Medical treatment of gastroesophageal reflux disease
Yıl: 2017 Cilt: 28 Sayı: 1 Sayfa Aralığı: 48 - 52 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022
Medical treatment of gastroesophageal reflux disease
Öz: Proton pump inhibitors (PPIs) are the most effective agents in the first-line and maintenance treatment of gastroesophageal reflux disease. As the grade of esophagitis increases, an increase is also observed in the level of endoscopic response to PPIs. In the first-line therapy of patients with severe esophagitis (Los Angeles (LA) Grade C-D), administration of a standard dose of PPIs bid has been reported to be more beneficial than PPIs qd. While any intermittant and low dose-continuous treatment can be chosen for the maintenance therapy of patients with non-erosive reflux disease or mild esophagitis (LA Grade A-B), continuous use of a standard dose of PPIs is preferred in the maintenance therapy of patients with severe esophagitis (LA Grade C-D). In patients who use PPIs for a long time, the drug must be stopped by gradually decreasing the dose
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Shortterm treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013; 5: CD002095.
- 2. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011; 106: 1419-25. [CrossRef]
- 3. Klok RM, Postma MJ, van Hout BA, Brouwers JR. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 2003; 17: 1237-45. [CrossRef]
- 4. Edwards SJ, Lind T, Lundell L, DAS R. Systematic review: standardand double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials. Aliment Pharmacol Ther 2009; 30: 547-56. [CrossRef]
- 5. Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus otherproton pump inhibitors in erosive esophagitis: a metaanalysis of randomized clinical trials. Clin Gastroenterol Hepatol 2006; 4: 1452-8. [CrossRef]
- 6. Armstrong D, Talley NJ, Lauritsen K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004; 20: 413-21. [CrossRef]
- 7. Richter JE, Fraga P, Mack M, Sabesin SM, Bochenek W; Pantoprazole US GERD Study Group. Prevention of erosive oesophagitis relapse with pantoprazole. Aliment Pharmacol Ther 2004; 20: 567-75. [CrossRef]
- 8. Chen WY, Chang WL, Tsai YC, Cheng HC, Lu CC, Sheu BS. Doubledosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. Am J Gastroenterol 2010; 105: 1046-52. [CrossRef]
- 9. Scott M, Gelhot AR. Gastroesophageal reflux disease,diagnosis and management. Am Fam Physician 1999; 59: 1161-9.
- 10. Williams LN. Gastroesophageal reflux disease. Canadian J Gastroenterology 1997; 92(Suppl 4): 22s-7s.
- 11. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; CD003245.
- 12. Scholten T, Teutsch I, Bohuschke M, Gatz G. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease. Clin Drug Investig 2007; 27: 287-96. [CrossRef]
- 13. Goh KL, Benamouzig R, Sander P, Schwan T; EMANCIPATE. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal re flux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. Eur J Gastroenterol Hepatol 2007; 19: 205-11.
- 14. Labenz J, Armstrong D, Lauritsen K, et al. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther. 2005 1;22: 803-11. Erratum in: Aliment Pharmacol Ther 2006; 23: 449.
- 15. Lauritsen K, Devière J, Bigard MA, et al; Metropole study results. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther 2003; 17: 333-41. [CrossRef]
- 16. Scholten T, Dekkers CP, Schütze K, Körner T, Bohuschke M, Gatz G. On-demand therapy with pantoprazole 20 mg as effective longterm management of reflux disease in patients with mild GERD: the ORION trial. Digestion 2005; 72: 76-85. [CrossRef]
- 17. Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002; 14: 857-63. [CrossRef]
- 18. Caos A, Breiter J, Perdomo C, Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther 2005; 22: 193-202. [CrossRef]
- 19. Sjöstedt S, Befrits R, Sylvan A, Harthon C, Jörgensen L, Carling L, Modin S, Stubberöd A, Toth E, Lind T. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005; 22: 183-91. [CrossRef]
- 20. Morgan DG, O'Mahony MF, O'Mahony WF, et al. RAB-GRD-3002 Study Group. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg. Can J Gastroenterol 2007; 21: 820-6. [CrossRef]
- 21. Pace F, Negrini C, Wiklund I, Rossi C, Savarino V. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005; 22: 349-56. [CrossRef]
- 22. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907-14. [CrossRef]
- 23. Fass R, Delemos B, Nazareno L, Kao R, Xiang J, Lu Y. Clinical trial:maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study. Aliment Pharmacol Ther 2010; 31: 950-60.
- 24. Festen HP, Schenk E, Tan G, Snel P, Nelis F. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group. Am J Gastroenterol 1999; 94: 931-6. [CrossRef]
- 25. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903-12. [CrossRef]
- 26. Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999; 116: 239-47. [CrossRef]
- 27. Lødrup AB, Reimer C, Bytzer P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scand J Gastroenterol 2013; 48: 515-22. [CrossRef]
- 28. Hunfeld NG, Geus WP, Kuipers EJ. Systematic review: Rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther 2007; 25: 39-46. [CrossRef]
| APA | Bor S, KALKAN İ (2017). Medical treatment of gastroesophageal reflux disease. , 48 - 52. |
| Chicago | Bor Serhat,KALKAN İsmail Hakkı Medical treatment of gastroesophageal reflux disease. (2017): 48 - 52. |
| MLA | Bor Serhat,KALKAN İsmail Hakkı Medical treatment of gastroesophageal reflux disease. , 2017, ss.48 - 52. |
| AMA | Bor S,KALKAN İ Medical treatment of gastroesophageal reflux disease. . 2017; 48 - 52. |
| Vancouver | Bor S,KALKAN İ Medical treatment of gastroesophageal reflux disease. . 2017; 48 - 52. |
| IEEE | Bor S,KALKAN İ "Medical treatment of gastroesophageal reflux disease." , ss.48 - 52, 2017. |
| ISNAD | Bor, Serhat - KALKAN, İsmail Hakkı. "Medical treatment of gastroesophageal reflux disease". (2017), 48-52. |
| APA | Bor S, KALKAN İ (2017). Medical treatment of gastroesophageal reflux disease. Turkish Journal of Gastroenterology, 28(1), 48 - 52. |
| Chicago | Bor Serhat,KALKAN İsmail Hakkı Medical treatment of gastroesophageal reflux disease. Turkish Journal of Gastroenterology 28, no.1 (2017): 48 - 52. |
| MLA | Bor Serhat,KALKAN İsmail Hakkı Medical treatment of gastroesophageal reflux disease. Turkish Journal of Gastroenterology, vol.28, no.1, 2017, ss.48 - 52. |
| AMA | Bor S,KALKAN İ Medical treatment of gastroesophageal reflux disease. Turkish Journal of Gastroenterology. 2017; 28(1): 48 - 52. |
| Vancouver | Bor S,KALKAN İ Medical treatment of gastroesophageal reflux disease. Turkish Journal of Gastroenterology. 2017; 28(1): 48 - 52. |
| IEEE | Bor S,KALKAN İ "Medical treatment of gastroesophageal reflux disease." Turkish Journal of Gastroenterology, 28, ss.48 - 52, 2017. |
| ISNAD | Bor, Serhat - KALKAN, İsmail Hakkı. "Medical treatment of gastroesophageal reflux disease". Turkish Journal of Gastroenterology 28/1 (2017), 48-52. |
